Blau Farmacêutica S.A. Stock

Equities

BLAU3

BRBLAUACNOR8

Pharmaceuticals

Delayed Sao Paulo 12:53:06 2024-05-08 pm EDT 5-day change 1st Jan Change
10.44 BRL +1.00% Intraday chart for Blau Farmacêutica S.A. +2.25% -36.32%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 1.6B 316M Sales 2025 * 1.79B 355M Capitalization 1.87B 369M
Net income 2024 * 199M 39.35M Net income 2025 * 260M 51.41M EV / Sales 2024 * 1.31 x
Net Debt 2024 * 220M 43.59M Net Debt 2025 * 328M 64.94M EV / Sales 2025 * 1.22 x
P/E ratio 2024 *
9 x
P/E ratio 2025 *
7.47 x
Employees 1,900
Yield 2024 *
2.67%
Yield 2025 *
3.21%
Free-Float 16.44%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Blau Farmacêutica S.A., Q4 2023 Earnings Call, Mar 20, 2024
Blau Farmacêutica S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Blau Farmacêutica S.A., Q3 2023 Earnings Call, Nov 09, 2023
Blau Farmacêutica S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Blau Farmacêutica S.A., Q2 2023 Earnings Call, Aug 10, 2023
Tranche Update on Blau Farmacêutica S.A.'s Equity Buyback Plan announced on June 14, 2022. CI
Blau Farmacêutica S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Blau Farmacêutica S.A. completed the acquisition of Laboratorio Quimico Farmaceutico Bergamo Ltda from Amgen Inc. for $33.2 million. CI
Transcript : Blau Farmacêutica S.A., Q1 2023 Earnings Call, May 05, 2023
Tranche Update on Blau Farmacêutica S.A.'s Equity Buyback Plan announced on June 14, 2022. CI
Blau Farmacêutica S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tranche Update on Blau Farmacêutica S.A.'s Equity Buyback Plan announced on June 14, 2022. CI
Blau Farmacêutica S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on Blau Farmacêutica S.A.'s Equity Buyback Plan announced on June 14, 2022. CI
Blau Farmacêutica S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
More news
1 day+1.55%
1 week+4.37%
Current month+4.37%
1 month-12.42%
3 months-15.92%
6 months-39.39%
Current year-35.95%
More quotes
1 week
9.96
Extreme 9.96
10.79
1 month
9.29
Extreme 9.29
12.12
Current year
9.29
Extreme 9.29
16.42
1 year
9.29
Extreme 9.29
22.56
3 years
9.29
Extreme 9.29
54.92
5 years
9.29
Extreme 9.29
54.92
10 years
9.29
Extreme 9.29
54.92
More quotes
Managers TitleAgeSince
Founder - 87-12-17
Director of Finance/CFO - 18-04-30
Compliance Officer - 13-12-31
Members of the board TitleAgeSince
Director/Board Member 61 -
Chief Operating Officer 58 -
Founder - 87-12-17
More insiders
Date Price Change Volume
24-05-08 10.44 +1.00% 355 900
24-05-07 10.51 +1.55% 228,800
24-05-06 10.35 -1.71% 228,400
24-05-03 10.53 +3.03% 387,600
24-05-02 10.22 +1.49% 369,300

Delayed Quote Sao Paulo, May 07, 2024 at 04:07 pm EDT

More quotes
Blau Farmaceutica SA is a Brazil-based company engaged in the pharmaceuticals sector. The Company focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The Company operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
7
Last Close Price
10.51 BRL
Average target price
13.57 BRL
Spread / Average Target
+29.13%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW